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The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will
need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma
progression and suggest possible drug combinations for future clinical testing.
British Journal of Cancer (2009) 100, 431–435. doi:10.1038/sj.bjc.6604891 www.bjcancer.com
Published online 20 January 2009
& 2009 Cancer Research UK
Keywords: melanoma; targeted therapy; BRAF; PI3K; mTOR; PTEN; chemotherapy
                            
The discovery of activating oncogenic mutations in BRAF in over
60% of melanomas has raised expectations that melanoma may be
amenable to targeted therapy. The most prevalent mutation in
BRAF is at the V600E position, resulting in the substitution of
valine to glutamate and destabilisation of the inactive kinase
conformation switching the equilibrium towards the active form
(Gray-Schopfer et al, 2007). Most of the transforming activity of
the BRAF V600E is thought to result through the activation of the
mitogen-activated protein kinase (MAPK) pathway (Gray-Schopfer
et al, 2007). Regardless of BRAF V600E mutational status, virtually
all melanomas have activity in the MAPK pathway (Satyamoorthy
et al, 2003), and this contributes to the oncogenic phenotype of
melanoma through its effects on cell proliferation, invasion and
survival (Gray-Schopfer et al, 2007). In experimental systems, the
role of BRAF in melanoma seems convincing. In vitro studies have
shown that BRAF V600E is an oncogene in immortalised mouse
melanocytes (Gray-Schopfer et al, 2007), and the selective down-
regulation of BRAF V600E using RNAi causes cell death and
reversal of the melanoma phenotype (Hingorani et al, 2003).
However, pharmacological inhibition of BRAF and MEK have not
produced such dramatic effects in vivo (Sharma et al, 2005; Haass
et al, 2008). This is partly due to inherent flaws in the agents tested
to date, and also a likely indication of the greater vulnerability of
melanoma cells in vitro where most of the cells are rapidly cycling
under sub-confluent culture conditions in the continuous presence
of serum.
PRECLINICAL STUDIES ON BRAF/MEK INHIBITORS
The first putative BRAF inhibitor to be developed was sorafenib
(Nexavar
s, BAY 43-9006). A number of studies have now shown
that sorafenib induces melanoma cell apoptosis in vitro and
reduces the growth of human melanoma xenografts in mice
(Sharma et al, 2005). Although it was shown that phospho-MEK
was blocked at the concentrations of sorafenib used, only relatively
minor levels of apoptosis were observed in vivo, suggestive of
alternative mechanisms of action. It was later shown that sorafenib
treatment reduced the vascularisation of melanoma xenografts
(Sharma et al, 2005), and that the compound was a relatively
potent VEGF receptor inhibitor.
A number of more specific BRAF inhibitors have now been
developed, some of which have relative selectivity for the BRAF
V600E mutation compared with wild-type BRAF, such as SB590885
(GlaxoSmithKline, Collegeville, PA, USA) (King et al, 2006) and
PLX-4032/PLX-4720 (Plexxikon, Berkley, CA, USA) (Tsai et al, 2008).
As selective BRAF targeted compounds have relatively few
off-target effects, it is now possible to assess the effects of specific
pharmacological inhibition of BRAF in melanoma. An extensive
characterisation of SB590885 has shown that the compound is highly
selective for cell lines with BRAF mutations, accompanied by a
profound inhibition of cell growth associated with the induction of
G1-phase cell cycle arrest (King et al, 2006). Interestingly, SB590885
activity against human melanoma xenografts in mice is fairly weak,
and there is merely a delay in the onset of tumor growth. The
interpretation of these results is somewhat hindered by the poor
pharmacological properties of this agent. Similar G1-phase growth
arrest results have been observed with allosteric MEK inhibitors,
such as U0126, PD0325901 and AZD6244, suggesting that inhibition
of the MAPK pathway in melanoma is largely cytostatic (Smalley
et al, 2006; Solit et al, 2006; Haass et al,2 0 0 8 ) .A c t i v a t i n gBRAF
V600E mutations are also known to occur in subsets of thyroid and
colon carcinomas (Davies et al,2 0 0 2 ) ,a n ds i m i l a rt om e l a n o m a ,t h e
presence of the mutation also predicts for sensitivity to MEK
inhibition (Solit et al, 2006; Leboeuf et al, 2008). There is evidence
that PLX-4032 and its tool-compound counterpart PLX-4720 induces
some limited apoptosis in melanoma cell lines with the V600E
mutation but not in those that are BRAF wild type (Tsai et al, 2008).
G i v e nt h ep i v o t a lr o l eo fBRAF in melanoma progression, it is
somewhat surprising that these pharmacological inhibitors do not
generally induce much apoptosis. Recent studies have shown that
blocking the MAPK pathway did not affect the levels of Bcl-2, Bcl-XL
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www.bjcancer.comor Mcl-1 expression (Verhaegen et al, 2006). Knockdown of the
BH3-family protein Mcl-1 using shRNA sensitised the melanoma
cells to U0126-induced apoptosis, showing that overexpression of
these key anti-apoptotic proteins in melanoma is a critical barrier to
an effective BRAF/MEK inhibitor therapy. It is therefore suggested
that melanoma cells recruit additional survival mechanisms that are
MAPK pathway-independent.
WHY COMBINATION THERAPIES ARE NEEDED IN
MELANOMA
It is likely that as the melanomas progress, there is functional
redundancy between the numerous signalling pathways (Figure 1).
Earlier studies from our laboratory, using cell lines derived from
metastatic lesions, confirm this hypothesis and demonstrate that
cells are resistant to both MEK and PI3K inhibitors when grown in
3D culture (Smalley et al, 2006). It was further shown that targeting
either the PI3K or MEK pathway alone led to cytostasis and was
associated with a reversible G1-phase cell cycle arrest (Smalley
et al, 2006; Haass et al, 2008). In other studies, there was a lack of
good correlation between the inhibition of either the PI3K or MEK
signalling pathway and the inhibition of cell growth, showing a
functional redundancy between the various growth-promoting
signalling pathways. These findings also translated into in vivo
studies, where the MEK inhibitor AZD6244 led to the stabilisation
of established human melanoma xenografts, but not tumor
regression (Haass et al, 2008). Furthermore, this suggests that
the effects of MEK inhibition in this setting were largely cytostatic.
This lack of good cytotoxic activity after either MEK or PI3K
inhibition alone suggests that multiple signalling pathways need to
be targeted simultaneously to induce melanoma regression.
It is currently unclear how well the preclinical findings on the
role of BRAF in melanoma cell lines match with the clinical
observations on the role of BRAF in melanoma pathogenesis. A
number of reports have suggested that the levels of phospho-ERK
staining are often variable in patient tumors and do not correlate
with the BRAF/NRAS mutational status (Houben et al, 2008). Even
in melanomas that are the most sensitive, prolonged BRAF/MEK
inhibitor treatment may lead to the rapid acquisition of drug
resistance. Earlier studies have shown that prolonged treatment
(46 months) with the MEK inhibitor CI-1040 leads to a 100-fold
loss of potency in apoptosis and colony formation assays
associated with increased expression of activated KRAS (Wang
et al, 2005). Some of the first reports have now appeared indicating
that melanoma cells can also become resistant to BRAF inhibitors
after continuous drug exposure. Treatment of melanoma cells with
the BRAF inhibitor AZ628 led to the development of clones that
maintained high phospho-ERK levels and continued to proliferate
in the presence of drug (Montagut et al, 2008). In this instance,
resistance was associated with a switching from BRAF to CRAF
signalling, an effect that could be reversed by treatment with the
heat shock protein (HSP)-90 inhibitor geldanamycin (Montagut
et al, 2008). There is also recent evidence from our group
demonstrating that some melanomas with BRAF V600E mutations
may be intrinsically resistant to inhibitors of BRAF as a result of
cyclin D1 amplification (Smalley et al, 2008).
The key question facing the field is what combination of signal
transduction inhibitors are needed to achieve the maximal
cytotoxic effect, and whether the combination of inhibitors is
determined by the underlying genetics of the tumor?
SUITABLE COMBINATION TARGETS: THE PI3K
PATHWAY?
Mitogen-activated protein kinase is not the only pathway to be
constitutively active in melanoma (Figure 1). Another key pathway
involved in cell survival, growth and apoptosis suppression is the
PI3K/AKT pathway. Melanomas generally lack PI3K and AKT
mutations, but PTEN is lost in 30% of cell lines and B10% of
clinical melanoma specimens. Recent studies have shown that AKT
is able to transform melanocytes under hypoxic conditions
(Bedogni et al, 2005), and there is evidence of cooperation
between BRAF V600E and AKT in melanoma development
(Cheung et al, 2008). Of the three AKT family members (AKT1–
3), about 50% of melanoma cells have constitutive activity in AKT3
(Stahl et al, 2004). Inhibition of AKT activity in melanoma, using
either PI3K inhibitors or selective RNAi to AKT3, or both, reduces
growth and induces some degree of apoptosis (Stahl et al, 2004).
There is preclinical evidence to suggest that there is a synergistic
anti-melanoma activity when MEK and PI3K/AKT are inhibited
concomitantly. Thus, the topical application of U0126 and
LY294002 led to the regression of xenografts in a TPRas-induced
melanoma model (Bedogni et al, 2004) associated with
increased apoptosis and a reduced angiogenic response. Other
studies have shown that PI3K and MEK inhibitors synergise
to reduce growth and survival of melanoma cell lines grown under
3D organotypic cell culture conditions (Smalley et al, 2006;
Meier et al, 2007). There is also evidence that siRNA knockdown of
AKT3 and BRAF V600E leads to the enhanced inhibition of
melanoma xenograft growth in nude mice (Cheung et al, 2008;



























Figure 1 Sample signalling scheme showing pathways known to be
active in melanoma. Preclinical studies support the combined targeting of
either BRAF/MAPK and PI3K/AKT pathway or the BRAF/MAPK and mTOR
signalling pathways in melanoma. It is likely that the combined inhibition of
BRAF/PI3K pathways will have synergistic effects at the level of growth
inhibition, via effects upon cyclin D1 expression, as well as through
increased expression of the cyclin dependent kinase inhibitor p21
waf-1/cip-1.
Inhibition of the AKT/mTOR pathway is likely to affect cell survival via
modulation of BAD/Bcl-2, as well as affecting protein translation at the level
of S-6-kinase (S6K).
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SIGNALLING?
The mammalian target of rapamycin (mTOR) is a kinase that
occupies a pivotal position in growth factor receptor and nutrient
availability signalling, and has important downstream effects on
cell growth and survival. It is also a part of the AKT signalling
pathway and regulates the activity of this kinase in complex ways.
Mammalian target of rapamycin can either positively or negatively
regulate AKT signalling, and this is dependent on the composition
of the mTOR signalling complex. Thus, mTOR forms at least two
protein signalling complexes called mTORC1 and mTORC2.
mTORC1 consists of mTOR, as well as the regulatory proteins
raptor and mLST8. Activation of the mTORC1 signalling complex
leads to the phosphorylation and activation of p70 S6kinase (S6K)
and the eukaryotic initiation factor 4E-binding protein (4EBP1)
(Reiling and Sabatini, 2006). In contrast, the mTORC2 complex
also consists of mTOR and mLST8, and additionally includes the
regulatory proteins rictor and mSin-1. The differences between the
two mTOR complexes are highly relevant, as an active mTORC1
complex suppresses AKT signalling, whereas mTORC2 stimulates
AKT signalling through a phosphorylation event. A number of
small molecule inhibitors are available that target mTORC1 but not
mTORC2 signalling. The best characterised of these is rapamycin,
a drug which is currently FDA-approved for use as an
immunosuppressive agent after organ transplantation. There is
evidence from the literature that mTOR signalling is active in
melanoma. Studies have shown the presence of constitutive
phospho-S6K in a high proportion of metastatic melanoma
samples (Karbowniczek et al, 2008). Further work has shown that
rapamycin has growth inhibitory effects across a panel of human
melanoma cell lines (Molhoek et al, 2005), and there is evidence of
synergistic pro-apoptotic activity between sorafenib/MEK
inhibitors and rapamycin in preclinical models of melanoma
(Molhoek et al, 2005; Meier et al, 2007; Lasithiotakis et al, 2008).
Mechanistically, it seems that combined MEK/mTOR inhibition
reduces the expressions of Mcl-1 and Bcl-2, two proteins that are
known to suppress apoptosis induction in melanoma cells
(Lasithiotakis et al, 2008).
SUITABLE COMBINATION TARGETS:
CHEMOTHERAPY
Although most attention preclinically is focused on the combined
inhibition of signal transduction pathways, most clinical interest is
focused on the combination of targeted therapy agents with
chemotherapy. Already, there are early suggestions that sorafenib
may enhance the activity of carboplatin/paclitaxel and dacarbazine
(McDermott et al, 2008). From a biochemical standpoint, very little
is known about how MAPK signalling may modulate responses to
chemotherapy, although it is known that constitutive MAPK
activity, arising from mutations in HRAS, mediates cisplatin
resistance through an increased DNA repair activity (Yen et al,
1997). There is evidence for the role of MEK in the upregulation of
the DNA repair genes XRCC1 and ERCC1 after DNA damage and
that this may be mediated by the transcription factor GATA-1
(Andrieux et al, 2007).
Rather more is known about the interaction between MEK
inhibitors and the microtubule-stabilising taxanes. Treatment of
cancer cells with paclitaxel is known to activate the MAPK
pathway, and inhibition of MEK in combination with paclitaxel
leads to additive effects on cell growth inhibition and apoptosis
induction. It has also been shown that in addition to its effect on
the G1/S-phase cell cycle transition, MAPK activity is also critical
during meiosis and mitosis. Activated MAPK components
(including BRAF) localise to the asters and kinetochores during
mitosis, as well as to the actin-microtubule cytoskeleton. Earlier
studies have shown that the orally available MEK inhibitor CI-1040
enhances the efficacy of paclitaxel in lung cancer xenograft models
(McDaid et al, 2005), and that the MEK inhibitor AZD6244
enhances the pro-apoptotic effects of docetaxel in human
melanoma cells (Haass et al, 2008). There is some suggestion that
this combination may be effective because MEK activity is required
for successful execution of mitosis, and the co-administration of
an MEK inhibitor and paclitaxel enhances the level of mitotic
catastrophe. These combinations are now undergoing evaluation
for a number of solid tumors in phase I clinical trials, and a
randomised phase II trial comparing AZD6244 combined with
docetaxel, with docetaxel alone is planned.
CLINICAL STUDIES ON BRAF/MEK INHIBITORS
The current expectation is that BRAF inhibitors will be used in
combination with either other targeted therapy agents or
established chemotherapy regimens. However, it is necessary to
rigorously evaluate each of the novel BRAF and MEK inhibitors as
single agents so that we understand their distinct pharmacological
properties and their respective abilities to hit their target and
perturb proliferation or cell viability. Only with this knowledge can
we make an informed selection of agents for further development.
Sorafenib is the most thoroughly investigated signal transduc-
tion inhibitor in clinical trials of melanoma patients. As a single
agent, it was associated with only one objective response among 61
patients (Eisen et al, 2006). A small subset of patients with
previously progressive metastatic disease maintained stable
disease for more than 6 months, but an insufficient number to
support the inclusion of sorafenib into a randomised phase III trial
as a single agent. Analysis of patient samples pre- and posttreat-
ment revealed that sorafenib incompletely inhibited ERK phos-
phorylation. This observation may be significant as preclinical
studies show that complete pathway inhibition is needed to induce
cell cycle arrest (Solit et al, 2006; Haass et al, 2008). In the
single-agent phase II trials with sorafenib, the common toxicities
were hypertension and hand-foot syndrome, consistent with the
toxicities described with inhibitors of VEGF signalling. On the
basis of these observations, the inhibitory activity of sorafenib
against VEGF receptors (VEGFR2, VEGFR3 and VEGFR1) was
explored with dynamic contrast-enhanced MRI and the results
supported such an effect.
The combination of sorafenib with either carboplatin/paclitaxel
or temozolomide has suggested some benefits. Consistent with the
hypothesis that sorafenib is a weak inhibitor of BRAF in humans,
an association between BRAF mutation and benefit from
sorafenib/chemotherapy regimens has not been observed (Flaherty
et al, 2008). A small, randomised phase II trial suggested benefit
when sorafenib was added to dacarbazine compared with
dacarbazine alone (McDermott et al, 2008). A phase III trial
comparing sorafenib combined with chemotherapy with
chemotherapy alone in patients with melanoma has completed
accrual and results are expected in late 2009. The mechanism by
which sorafenib appears to enhance the cytotoxicity of chemo-
therapy remains in question, and is complicated by the broad-
spectrum anti-kinase activity of sorafenib. Although there is
evidence that MEK inhibition may sensitise cells to certain
chemotherapies, it is not clear whether this mechanism is shared
by sorafenib. A number of other studies have shown that inhibitors
of VEGF signalling, such as bevacizumab, synergise with
chemotherapy drugs, suggesting that the anti-VEGF activity of
sorafenib may underlie its interaction with chemotherapy (Folkins
et al, 2007). The broad-spectrum effects of sorafenib also leave
open the possibility that anti-tumor immunity may be impaired
after treatment (Hipp et al, 2008). As partial MAP kinase pathway
inhibition, angiogenesis inhibition and suppression of anti-tumor
response might combine to be effective in some patients, but
counter-productive in others, significant additional work remains
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sorafenib/chemotherapy approach. Some clinical studies have
suggested that the presence of BRAF mutations confers a lower
likelihood of response or disease control with multi-agent
chemotherapy regimens (Kumar et al, 2003) . This is clearly an
area deserving further investigation, as it is unclear whether
inhibition of BRAF would reverse this resistance, or whether that
property is mediated through other pathways.
The MEK inhibitors—PD0325901 and AZD6244—have also
progressed through phase I, and in the case of AZD6244 phase II
clinical trials. PD0325901 has been evaluated in a phase I trial, in
which most of the patients had melanoma. Of these patients, some
experienced an objective response (2 out of 27) and 5 additional
patients showed some disease stabilisation. Dose-limiting diar-
rhoea and rash precluded further dose escalation and possibly
preclude the delivery of a dose required to adequately suppress the
MAPK pathway. Phase II trials of this drug were suspended
because of the occurrence of retinal vein thrombosis in several
patients. AZD6244 was evaluated in a phase I trial among patients
with advanced solid tumors (Adjei et al, 2008). Of the melanoma
patients treated, none had an objective response; however, four
patients maintained disease stabilisation for more than 6 months,
suggesting a clinical benefit. A randomised phase II trial was
completed among 200 patients with melanoma. Patients were
randomised in a 1:1 manner to AZD6244 or temozolomide
(Dummer et al, 2008). Five objective responses were observed
among 42 patients with BRAF V600E mutations (12% objective
response rate), indicating that a subset of BRAF mutant
melanomas may be sensitive to this agent. The trial was designed
to detect an improvement in progression-free survival compared
with single-agent temozolomide. As this activity was not seen,
AZD6244 was deemed insufficient to warrant further single-agent
clinical trials in melanoma.
As the preclinical data support the selective activity of RAF and
MEK inhibitors in BRAF mutant melanoma, it is logical to accrue
patients to phase II trials with these agents. This requires the
elaboration of real-time mutation screening for inclusion into
clinical trials, a hurdle not previously surmounted in earlier
targeted therapy trials in cancer. The identification of concomitant
genetic alterations or other markers of aberrant signal transduc-
tion in the same tumor samples used for BRAF mutation testing
will set the foundation for exploration of markers of response or
resistance. If a responsive subset of BRAF-mutated melanomas can
be identified, it may be possible to rapidly develop RAF and MEK
inhibitors as single agents for this population, whereas combina-
tion strategies are explored for the remaining.
Although the preclinical data are compelling in support of
combining BRAF inhibition with a PI3K/AKT or mTOR inhibitor,
the availability of agents targeting the mediators for phase I
combination trials is severely limited. Potent and selective PI3K or
AKT inhibitors are currently used in phase I clinical trials. As they
emerge from phase I trials, there is the possibility of evaluating
rational combinations with selective RAF or MEK inhibitors. Only
rapamycin-analog mTOR inhibitors are readily available. It is not
clear that these agents adequately block the upstream activation of
this pathway, as they only block TORC1 complex signalling and
permit enhanced activation of AKT by TORC2. A phase II trial was
conducted with single-agent temsirolimus in 33 patients with
metastatic melanoma unselected for any molecular or genetic
features (Margolin et al, 2005). One partial response was observed
and median progression-free survival was just over 2 months,
consistent with an inactive therapy. However, there was little
reason to hope that this therapy would have a stand-alone role.
Rapamycin analogs are sufficiently tolerable to be evaluated in
combination with other agents, and are presently the only agents
one can feasibly combine with emerging BRAF or MEK inhibitors.
CONCLUSION
Although MAPK activation is a key step in the oncogenic
transformation of melanocytes into melanoma, it appears that
only a small minority of patients will benefit from the single-agent
BRAF/MEK inhibitor treatment. The redundancy within the
multiple signalling pathways activated in melanoma, along with
the likelihood of drug resistance, suggests that combination
therapy strategies will be required for effective disease manage-
ment. It is further likely that the same molecular pathways
involved in melanoma progression will also play important roles in
both the angiogenic and immune response of melanoma, so that
the targeting of these molecular pathways may have other
beneficial effects beyond growth inhibition. As melanomas are
more genetically heterogeneous than first thought, it is likely that
‘personalised’ combination therapies will need to be developed,
whereby patient therapy is dictated by the constellation of
mutations found within their tumors. The idea of personalised
cancer therapy has already been demonstrated by the use of
epidermal growth factor receptor inhibitors in lung cancer, where
only B10% of patients harbour epidermal growth factor mutations
and most fit a particular profile (adenocarcinoma, never-smoker,
East-Asian ethnic origin and female). Similarly, in melanoma,
there are early reports of success when selected groups of patients
harbouring activating mutations in the receptor tyrosine kinase
c-KIT have been treated with imatinib (Hodi et al, 2008). Clearly,
there is much still to do, but we believe that targeting the correct
combinations of signalling pathways in carefully selected groups of
patients could give the therapeutic breakthrough that has been
long overdue in melanoma.
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